Loading...

Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. Many mCRPC patients never receive chemotherapy and thus cannot benefit from abiraterone acetate; we evaluated this agent i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Ryan, Charles J., Smith, Matthew R., de Bono, Johann S., Molina, Arturo, Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, JM, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A., Basch, Ethan, Small, Eric J., Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D., Suttmann, Henrik, Gerritsen, Winald R., Flaig, Thomas W., George, Daniel J., Yu, Evan Y., Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S., Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I., Rathkopf, Dana E.
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683570/
https://ncbi.nlm.nih.gov/pubmed/23228172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1209096
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!